Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PTEN_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PTEN_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PTEN_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PTEN_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PTEN_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PTEN_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PTEN_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PTEN_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PTEN_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:009013023 | Oral cavity | NEOLP | tissue migration | 78/2005 | 365/18723 | 1.61e-09 | 1.06e-07 | 78 |
GO:009013223 | Oral cavity | NEOLP | epithelium migration | 77/2005 | 360/18723 | 1.96e-09 | 1.24e-07 | 77 |
GO:001810522 | Oral cavity | NEOLP | peptidyl-serine phosphorylation | 70/2005 | 315/18723 | 1.97e-09 | 1.24e-07 | 70 |
GO:005134833 | Oral cavity | NEOLP | negative regulation of transferase activity | 62/2005 | 268/18723 | 3.19e-09 | 1.91e-07 | 62 |
GO:190305034 | Oral cavity | NEOLP | regulation of proteolysis involved in cellular protein catabolic process | 54/2005 | 221/18723 | 4.32e-09 | 2.49e-07 | 54 |
GO:004593633 | Oral cavity | NEOLP | negative regulation of phosphate metabolic process | 88/2005 | 441/18723 | 5.20e-09 | 2.87e-07 | 88 |
GO:001056333 | Oral cavity | NEOLP | negative regulation of phosphorus metabolic process | 88/2005 | 442/18723 | 5.82e-09 | 3.15e-07 | 88 |
GO:001820922 | Oral cavity | NEOLP | peptidyl-serine modification | 72/2005 | 338/18723 | 7.84e-09 | 4.09e-07 | 72 |
GO:004232633 | Oral cavity | NEOLP | negative regulation of phosphorylation | 79/2005 | 385/18723 | 8.76e-09 | 4.48e-07 | 79 |
GO:190336433 | Oral cavity | NEOLP | positive regulation of cellular protein catabolic process | 41/2005 | 155/18723 | 2.87e-08 | 1.22e-06 | 41 |
GO:001635822 | Oral cavity | NEOLP | dendrite development | 55/2005 | 243/18723 | 5.38e-08 | 2.16e-06 | 55 |
GO:000193332 | Oral cavity | NEOLP | negative regulation of protein phosphorylation | 70/2005 | 342/18723 | 6.77e-08 | 2.61e-06 | 70 |
GO:000756831 | Oral cavity | NEOLP | aging | 69/2005 | 339/18723 | 1.05e-07 | 3.83e-06 | 69 |
GO:003300221 | Oral cavity | NEOLP | muscle cell proliferation | 55/2005 | 248/18723 | 1.11e-07 | 4.03e-06 | 55 |
GO:200123532 | Oral cavity | NEOLP | positive regulation of apoptotic signaling pathway | 34/2005 | 126/18723 | 2.55e-07 | 8.23e-06 | 34 |
GO:007048232 | Oral cavity | NEOLP | response to oxygen levels | 69/2005 | 347/18723 | 2.66e-07 | 8.54e-06 | 69 |
GO:000166632 | Oral cavity | NEOLP | response to hypoxia | 63/2005 | 307/18723 | 2.75e-07 | 8.78e-06 | 63 |
GO:190188814 | Oral cavity | NEOLP | regulation of cell junction assembly | 47/2005 | 204/18723 | 2.82e-07 | 8.96e-06 | 47 |
GO:003629332 | Oral cavity | NEOLP | response to decreased oxygen levels | 65/2005 | 322/18723 | 3.34e-07 | 1.04e-05 | 65 |
GO:006007031 | Oral cavity | NEOLP | canonical Wnt signaling pathway | 62/2005 | 303/18723 | 3.79e-07 | 1.15e-05 | 62 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PTEN | SNV | Missense_Mutation | rs121909229 | c.389N>A | p.Arg130Gln | p.R130Q | P60484 | protein_coding | deleterious(0.02) | probably_damaging(0.998) | TCGA-A2-A4RX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PTEN | SNV | Missense_Mutation | | c.404T>A | p.Ile135Lys | p.I135K | P60484 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-A7-A26G-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
PTEN | SNV | Missense_Mutation | rs121909229 | c.389G>A | p.Arg130Gln | p.R130Q | P60484 | protein_coding | deleterious(0.02) | probably_damaging(0.998) | TCGA-A7-A4SC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
PTEN | SNV | Missense_Mutation | | c.593N>A | p.Met198Lys | p.M198K | P60484 | protein_coding | deleterious(0) | benign(0.285) | TCGA-AC-A2FF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
PTEN | SNV | Missense_Mutation | | c.384N>C | p.Lys128Asn | p.K128N | P60484 | protein_coding | deleterious(0.03) | probably_damaging(0.998) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
PTEN | SNV | Missense_Mutation | | c.28N>C | p.Ser10Arg | p.S10R | P60484 | protein_coding | deleterious(0) | benign(0.188) | TCGA-AR-A1AJ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PTEN | SNV | Missense_Mutation | rs786201995 | c.70G>A | p.Asp24Asn | p.D24N | P60484 | protein_coding | deleterious(0) | benign(0.012) | TCGA-AR-A1AM-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
PTEN | SNV | Missense_Mutation | | c.367C>G | p.His123Asp | p.H123D | P60484 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AR-A24Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
PTEN | SNV | Missense_Mutation | | c.370N>A | p.Cys124Ser | p.C124S | P60484 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AR-A2LL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
PTEN | SNV | Missense_Mutation | rs121909229 | c.389N>A | p.Arg130Gln | p.R130Q | P60484 | protein_coding | deleterious(0.02) | probably_damaging(0.998) | TCGA-AR-A5QQ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | PI3KBETA INHIBITOR AZD8186 | | 25544636 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | TEMSIROLIMUS | TEMSIROLIMUS | 11504908,23674493 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | Temsirolimus | TEMSIROLIMUS | 27016228 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | PF-04691502 | PF-04691502 | 21750219 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | PANITUMUMAB | PANITUMUMAB | 19223544 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | Oxaliplatin | OXALIPLATIN | 24100628 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | DETD-35 | | 27048951 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | cisplatin | CISPLATIN | |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | Copanlisib | COPANLISIB | 27672108 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | Fulvestrant | FULVESTRANT | 26733612 |